Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology
Pyramid Biosciences, Inc., a clinical-stage, biotechnology company developing novel precision therapies, announced that it has commenced a Phase 1 clinical study for its therapeutic candidate PBI-100, a first-in-class topical treatment targeting mild to moderate psoriasis in patients. Read more >>